City

Clinical trials near Guangzhou, China

Active studies with a listed research site in Guangzhou, China.

33active studies

18recruiting now

10countries represented

187largest site network

Current studies

Status and location data reflect the registry snapshot built 2026-09-08. Verify the original record before contacting a site.

Recruiting nowPhase 3

A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin

Overweight, ObesityCondition

Eloralintide, PlaceboTreatment

Australia, Belgium187 locations

Eli Lilly and CompanySponsor

Updated 2026-09-08 · NCT07392190See eligibility →

Recruiting nowPhase 3

A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes

Overweight, ObesityCondition

Eloralintide, PlaceboTreatment

Argentina, China157 locations

Eli Lilly and CompanySponsor

Updated 2026-09-08 · NCT07282600See eligibility →

Recruiting nowPhase 3

A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight

Urinary Incontinence,StressCondition

Orforglipron, PlaceboTreatment

Canada, China136 locations

Eli Lilly and CompanySponsor

Updated 2026-09-08 · NCT07202884See eligibility →

Recruiting nowPhase 3

A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight

Sleep Apnea, Obstructive, ObesityCondition

Eloralintide, PlaceboTreatment

Australia, Brazil115 locations

Eli Lilly and CompanySponsor

Updated 2026-09-08 · NCT07369011See eligibility →

Recruiting nowPhase 1

A Clinical Trial Evaluating TQF3250 Capsules in Patients With Type 2 Diabetes Mellitus and Overweight/Obesity

Type 2 Diabetes Mellitus Combined With Overweight or ObesityCondition

TQF3250 capsules, TQF3250 placeboTreatment

China12 locations

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Sponsor

Updated 2026-08-28 · NCT07747857See eligibility →

Recruiting nowPhase 3

AMAZE 4: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea

Obesity, OverweightCondition

NNC0487-0111, Placebo (matched to NNC0487-0111)Treatment

Australia, China92 locations

Novo Nordisk A/SSponsor

Updated 2026-08-04 · NCT07571109See eligibility →

Recruiting nowNot applicable

Efficacy and Safety of Akkermansia Muciniphila AKM Lab-01 for Overweight and Obesity

Overweight , ObesityCondition

AKM Lab-01, PlaceboTreatment

China1 locations

Moon (Guangzhou) Biotechnology Co., Ltd.Sponsor

Updated 2026-06-29 · NCT07331974See eligibility →

Recruiting nowNot applicable

Weight Loss Via Intelligent Guidance in Patients With Coronary Heart Disease and Obesity: a Randomized Clinical Trial

CHD, Overweight or ObeseCondition

dietary regulation and structured exercise trainingTreatment

China1 locations

Guangdong Provincial People's HospitalSponsor

Updated 2026-05-12 · NCT07514611See eligibility →

Recruiting nowPhase 1, Phase 2

Triple Hypoglycemic Regimens In Patients With Newly Diagnosed Type 2 Diabetes Mellitus

Type 2 DiabetesCondition

Semaglutide (1 Mg Dose), Sitagliptin (DPP4 inhibitor)Treatment

China1 locations

Second Affiliated Hospital of Guangzhou Medical UniversitySponsor

Updated 2026-01-28 · NCT07374328See eligibility →

Recruiting nowNot applicable

Mobile Applet for Weight Management in Obese Heart Failure Patients

Heart Failure, Overweight and ObesityCondition

Full usage of diet management app group and with the full usage of an intelligent weight scale, Limited usage of diet management app group and with the limited usage of an intelligent weight scaleTreatment

China26 locations

Heart Health Research CenterSponsor

Updated 2025-06-27 · NCT06455878See eligibility →

Recruiting nowNot applicable

Human Genes and Microbiota in Early Life

Host and Microbiome, Pregnancy OutcomesCondition

No interventionTreatment

China1 locations

Guangzhou Women and Children's Medical CenterSponsor

Updated 2025-04-13 · NCT06926166See eligibility →

Recruiting nowNot applicable

Maternal Grandmothers in the Born in Guangzhou Cohort Study

Hereditary Transmission, Immune DevelopmentCondition

Intervention not listedTreatment

China1 locations

Guangzhou Women and Children's Medical CenterSponsor

Updated 2024-10-01 · NCT03633162See eligibility →

Recruiting nowNot applicable

Modified Intermittent Eating on Weight Loss (INTEREST-3 Trial)

ObesityCondition

Intermittent fasting plus time-restricted eating, Calorie restrictionTreatment

China1 locations

Nanfang Hospital, Southern Medical UniversitySponsor

Updated 2024-06-24 · NCT06302803See eligibility →

Recruiting nowNot applicable

The Born in Guangzhou Cohort Study (BIGCS)

Intrauterine Hyperglycemia, Pregnancy OutcomesCondition

No interventionTreatment

China1 locations

Guangzhou Women and Children's Medical CenterSponsor

Updated 2024-02-26 · NCT02526901See eligibility →

Recruiting nowNot applicable

Twins Born in Guangzhou

Twin Diseases, Immune DevelopmentCondition

No interventionTreatment

China1 locations

Guangzhou Women and Children's Medical CenterSponsor

Updated 2024-02-26 · NCT03331133See eligibility →

Recruiting nowNot applicable

Chinese Obesity and MEtabolic Surgery Database (COMES Database)

Obesity, Metabolic SurgeryCondition

Metabolic and Bariatric SurgeryTreatment

China1 locations

Jinan University GuangzhouSponsor

Updated 2024-02-23 · NCT06275061See eligibility →

Recruiting nowNot applicable

GDM and Its Consequences in Mothers and Offsprings

Gestational Diabetes Mellitus, Pregnancy OutcomeCondition

Intervention not listedTreatment

China1 locations

Guangzhou Women and Children's Medical CenterSponsor

Updated 2023-09-13 · NCT04529889See eligibility →

Recruiting nowNot applicable

Nanshan Elderly Cohort Study

Hypertension, Type 2 Diabetes MellitusCondition

Intervention not listedTreatment

China2 locations

Sun Yat-sen UniversitySponsor

Updated 2018-06-26 · NCT03569735See eligibility →

Opening soonPhase 1

A Clinical Trial of TQF3250 Capsules in Overweight/Obese Trial Participants With Poor Weight Control Through Simple Lifestyle Intervention

Overweight/ObesityCondition

TQF3250 capsules, TQF3250 placeboTreatment

China10 locations

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Sponsor

Updated 2026-09-01 · NCT07798284See eligibility →

Opening soonPhase 3

A Study of Orforglipron (LY3502970) in Chinese Participants With Obesity or Overweight and Weight-Related Health Problems

Obesity, OverweightCondition

Orforglipron, PlaceboTreatment

China13 locations

Eli Lilly and CompanySponsor

Updated 2026-08-27 · NCT07790861See eligibility →

Opening soonNot applicable

Mazdutide for Remission of Type 2 Diabetes: Multicentre, Double Blind, Randomised, Placebo Controlled Trial

Diabetes Mellitus, Type 2Condition

Mazdutide, PlaceboTreatment

China1 locations

Yanbing LiSponsor

Updated 2026-08-17 · NCT07767552See eligibility →

Opening soonPhase 3

New Triple Combination Therapy in Newly Diagnosed Type 2 Diabetes

Diabetes MellitusCondition

Group A (triple combination intensive therapy group), Group B (standard therapy group)Treatment

China1 locations

Sun Yat-sen UniversitySponsor

Updated 2026-06-09 · NCT07635953See eligibility →

Opening soonNot applicable

Mazdutide as Adjuvant Therapy Following Sleeve Gastrectomy in Severe Obesity

Severe ObesityCondition

Sleeve gastrectomy plus early mazdutide initiation, Sleeve gastrectomy followed with early mazdutide placebo initationTreatment

China14 locations

Beijing Friendship HospitalSponsor

Updated 2025-08-21 · NCT07135141See eligibility →

Opening soonPhase 3

Aspirin 150 mg vs 100 mg for Prevention of Preeclampsia in High-Risk Obese Pregnant Women

PreeclampsiaCondition

Aspirin 100mg, Aspirin 150mgTreatment

China1 locations

FANG HESponsor

Updated 2025-05-08 · NCT06952712See eligibility →

Opening soonPhase 3

New Triple Therapy in Newly Diagnosed Type 2 Diabetes

Diabetes MellitusCondition

Group A (triple combination therapy group), Group B (standard therapy group)Treatment

China1 locations

Sun Yat-sen UniversitySponsor

Updated 2025-04-27 · NCT06946628See eligibility →

Active, not recruitingPhase 2

A Study of CS060380 Tablets in Patients With MASH and Obesity

Metabolic Dysfunction-associated Steatohepatitis (MASH), ObesityCondition

semaglutide, CS060380Treatment

China12 locations

Cascade Pharmaceuticals, IncSponsor

Updated 2026-08-10 · NCT07466017See eligibility →

Active, not recruitingNot applicable

Guangzhou Preterm and Term Birth Cohort Study

Preterm Birth, Neurodevelopmental DisordersCondition

No Intervention: Observational CohortTreatment

China1 locations

Sun Yat-sen UniversitySponsor

Updated 2026-08-10 · NCT07756177See eligibility →

Active, not recruitingPhase 3

A Study of Zovaglutide in Subjects With Overweight or Obesity (HORIZON-1)

Overweight , ObesityCondition

Zovaglutide dose 1, Zovaglutide dose 2Treatment

China45 locations

Beijing QL Biopharmaceutical Co.,LtdSponsor

Updated 2026-08-03 · NCT07230119See eligibility →

Active, not recruitingPhase 3

A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes

Obesity, OverweightCondition

Orforglipron, PlaceboTreatment

Argentina, China80 locations

Eli Lilly and CompanySponsor

Updated 2026-07-31 · NCT06993792See eligibility →

Active, not recruitingPhase 3

A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity

Obesity, OverweightCondition

Orforglipron, PlaceboTreatment

Argentina, China80 locations

Eli Lilly and CompanySponsor

Updated 2026-07-29 · NCT06972459See eligibility →

Active, not recruitingNot applicable

Anterolateral Thigh Myofascial Fat Composite Flap for Reconstruction of Hemiglossectomy Defects in Obese Patients With Tongue Cancer

Tongue CancerCondition

The anterolateral femoral myofascial fat composite flap (ALT-MF) repairs tongue defects in patients with tongue cancerTreatment

China1 locations

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversitySponsor

Updated 2026-07-06 · NCT07682467See eligibility →

Active, not recruitingPhase 3

A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes

Obesity, OverweightCondition

Orforglipron, PlaceboTreatment

Argentina, China80 locations

Eli Lilly and CompanySponsor

Updated 2026-04-20 · NCT06972472See eligibility →

Active, not recruitingPhase 2, Phase 3

The Efficacy and Safety of Efsubaglutide Alfa Injection in Overweight and Obese Subjects (ENLIGHT)

Obesity and OverweightCondition

Phase IIb：Efsubaglutide Alfa 5 mg QW, Phase IIb：Efsubaglutide Alfa 10 mg QWTreatment

China41 locations

Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.Sponsor

Updated 2026-01-30 · NCT06921486See eligibility →

How current is this page?

The page is rebuilt from the public registry feed. Each trial card shows the registry update date. Recruitment can still change between builds.

Does appearing here mean I qualify?

No. These pages are discovery indexes. Only a study team can confirm eligibility after reviewing the complete protocol criteria.

Clinical trials near Guangzhou, China

Current studies

Related cities